The goal is to further cement point of care as a mainstream media channel.
One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
If scientific storytelling alone can impact health outcomes, then how can we apply that knowledge in practice?
The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations
Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season
Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise
Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
With physicians spending nearly four hours a day on their electronic health records, experts say voice assistants could help reduce their workload one day.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
The deal highlights ongoing interest in the influential point-of-care market.
Fitness trackers do not reliably track calories, docs find; health-tech startups face market uncertainty; FDA adcom votes in favor of Puma breast-cancer drug
Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.
In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.
Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
Dr. Ashish Atreja is the director of the Sinai AppLab at the Icahn School of Medicine.
Dr. Susan Kornstein is co-founder and executive director of the Virginia Commonwealth University Institute for Women's Health.
Healthcare is one industry that hangs in this delicate balance, in large part due to the fact that it necessitates a blend of science and empathy.
Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.
Organizations are focusing on better ways to verify HCPs' digital identities.
He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.
Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March
The presumption is Dr. A saw ad B, clicked on it, went to the site and within C time, prescribed product D.